|
Advances in Chemoprevention
Chairperson: Powel H. Brown, The University of Texas MD Anderson Cancer Center, Houston, TX
- Powel H. Brown
- Patrick M. Lynch, The University of Texas MD Anderson Cancer Center, Houston, TX
- Eva Szabo, National Cancer Institute, Potomac, MD
- Ian M. Thompson, Jr., The University of Texas Health Science Center, San Antonio, TX
Androgen Receptors: Recent Advances in Targeting the Androgen Receptor for Prostate Cancer Prevention and Therapy
Chairperson: Steven P. Balk, Beth Israel Deaconess Medical Center, Boston, MA
- Steven P. Balk
- Peter S. Nelson, Fred Hutchinson Cancer Research Center, Seattle, WA
- Marianne Sadar, BC Cancer Foundation, Vancouver, BC, Canada
- Nancy Weigel, Baylor College of Medicine, Houston, TX
Antibody Engineering: Beyond Ehrlich’s Wildest Dreams
Chairperson: Hyam I. Levitsky, Hoffman-La Roche, Inc., Nutley, NJ
- Patrick A. Baeuerle, Micromet Corporation, Munich, Germany
- Hyam I. Levitsky
- Gail Lewis Phillips, Genentech, Inc., South San Francisco, CA
- Pablo Umana, Roche Glycart AG, Schlieren, Switzerland
Bench-to-Bedside Development of Next-Generation Immunotherapies
Chairperson: Larry W. Kwak, The University of Texas MD Anderson Cancer Center, Houston, TX
- Larry W. Kwak
- Yong-Jun Liu, The University of Texas MD Anderson Cancer Center, Houston, TX
- Drew M. Pardoll, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
- Laurence Zitvogel, Institut Gustave-Roussy, Villejuif, France
Beyond GWAS: Genes, Environment, and Rare Variants
Chairperson: Ulrike Peters, Fred Hutchinson Cancer Research Center, Seattle, WA
- Stacey Gabriel, Broad Institute of MIT and Harvard, Cambridge, MA
- Carolyn M. Hutter, Fred Hutchinson Cancer Research Center, Seattle, WA
- Peter L. Kraft, Harvard School of Public Health, Boston, MA
- Cristen Willer, University of Michigan, Ann Arbor, MI
BRCA, Genomics, and Women’s Health: A Global Perspective
Chairperson: Olufunmilayo I. Olopade, University of Chicago Medical Center, Chicago, IL
- Angela R. Bradbury, Fox Chase Cancer Center, Philadelphia, PA
- Georgia Chenevix-Trench, Queensland Institute of Medical Research, Brisbane, Australia
- Simon A. Gayther, University of Southern California, Los Angeles, CA
- Jeffrey N. Weitzel, City of Hope, Duarte, CA
Cancer Immunology for the Non-Immunologist, Tutorial
Co-Chairpersons: Suzanne Ostrand-Rosenberg, University of Maryland, Baltimore, MD; and Olivera J. Finn, University of Pittsburgh School of Medicine, Pittsburgh, PA
- Michael A. Caligiuri, The Ohio State University Comprehensive Cancer Center, Columbus, OH
- Mario P. Colombo, Istituto Nazionale Tumori, Milan, Italy
- Olivera J. Finn, University of Pittsburgh School of Medicine, Pittsburgh, PA
- Bernard A. Fox, Earle A. Chiles Research Institute, Portland, OR
- John G. Frelinger, University of Rochester Cancer Center, Rochester, NY
- Hyam I. Levitsky, Hoffman-La Roche, Inc., Nutley, NJ
- David M. Lubaroff, University of Iowa, Iowa City, IA
- Francesco M. Marincola, National Cancer Institute, Bethesda, MD
- Anna Karolina Palucka, Baylor University Medical Center, Dallas, TX
- Gregory E. Plautz, The Cleveland Clinic, Cleveland, OH
- Elizabeth A. Repasky, Roswell Park Cancer Institute, Buffalo, NY
- Suzanne L. Topalian, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
- Louis M. Weiner, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
- Weiping Zou, University of Michigan Medical School, Ann Arbor, MI
Cancer Signaling
Chairperson: Marcelo G. Kazanietz, University of Pennsylvania School of Medicine, Philadelphia, PA
- Kerry L. Burnstein, University of Miami Miller School of Medicine, Miami, FL
- Alan P. Fields, Mayo Clinic Florida, Jacksonville, FL
- Marcelo G. Kazanietz
- Alex Toker, Beth Israel Deaconess Medical Center, Boston, MA
Cancer Stem Cells: New Insights from New Approaches
Chairperson: Connie J. Eaves, BC Cancer Agency, Vancouver, BC, Canada
- Hanno Glimm, National Center for Tumor Diseases, Heidelberg, Germany
- R. Keith Humphries, University of British Columbia, Vancouver, BC, Canada
- Carla F. Kim, Children's Hospital Boston, Boston, MA
- Ali Turhan, Poitiers University Hospital, Poitiers, France
Cancer Survivorship: Role of Nutrition, Dietary Supplements, Physical Activity, and Weight Loss
Chairperson: Susan T. Mayne, Yale University School of Public Health, New Haven, CT
- Wendy Demark-Wahnefried, University of Alabama at Birmingham, Birmingham, AL
- Melinda L. Irwin, Yale University School of Public Health, New Haven, CT
- Susan T. Mayne
- Cheryl L. Rock, UCSD Moores Cancer Center, La Jolla, CA
Cancer Vaccines
Chairperson: Nina Bhardwaj, NYU School of Medicine, New York, NY
- Carl G. Figdor, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
- Sacha Gnjatic, Memorial Sloan-Kettering Cancer Center, New York, NY
- F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA
- Cornelis J.M. Melief, Leiden University Medical Center, Leiden, The Netherlands
Cell Cycle and Cancer
Chairperson: Piotr Sicinski, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
- Jiri Bartek, Danish Cancer Society, Copenhagen, Denmark
- René H. Medema, UMC Utrecht Cancer Center, Utrecht, The Netherlands
- Kei-Ichi Nakayama, Medical Institute of Bioregulation, Fukuoka, Japan
- Terry L. Orr-Weaver, MIT Whitehead Institute for Biomedical Research, Cambridge, MA
- Piotr Sicinski
Chemical Strategies for Modulating Protein-Protein Inhibition
Chairperson: James E. Bradner, Dana-Farber Cancer Inst., Boston, MA
- Guowei Fang, Genentech, Inc., South San Francisco, CA
- Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN
- Jun Qi, Dana-Farber Cancer Institute, Boston, MA
- Tomi Sawyer, Aileron Therapeutics, Cambridge, MA
Current Challenges in Molecular Marker Research
Chairperson: David F. Ransohoff, University of North Carolina, Chapel Hill, NC
- Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
- Lisa M. McShane, National Cancer Institute, Bethesda, MD
- David F. Ransohoff
Early Life Exposures in Cancer Etiology
Chairperson: Lawrence H. Kushi, Kaiser Permanente, Oakland, CA
- Michele R. Forman, The University of Texas at Austin, Austin, TX
- Randy L. Jirtle, Duke University Medical Center, Durham, NC
- Lawrence H. Kushi
- Cheryl Lyn Walker, The University of Texas MD Anderson Cancer Center, Smithville, TX
Established and Emerging Targets in Lung Cancer
Chairperson: Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
- Trever G. Bivona, University of California, San Francisco, CA
- Karen Cichowski, Brigham and Women's Hospital, Boston, MA
- Peter S. Hammerman, Dana-Farber Cancer Institute, Boston, MA
- Julien Sage, Stanford University School of Medicine, Stanford, CA
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 1: Targeting Tumor Heterogeneity with Novel Agent Combination Strategies
Chairperson: Matthew V. Lorenzi, Bristol-Myers Squibb Company, Princeton, NJ
- Channing J. Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
- Matthew V. Lorenzi
- Richard L. Schilsky, University of Chicago, Chicago, IL
- Jeffrey Settleman, Genentech, Inc., South San Francisco, CA
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 2: Challenges Validating New Targets for Cancer Drug Discovery
Chairperson: Dale A. Porter, Novartis Institutes for BioMedical Research, Cambridge, MA
- C. Glenn Begley, Oxford BioTherapeutics, Inc., Westlake Village, CA
- Dale A. Porter
- Frank P. Stegmeier, Novartis Institutes for BioMedical Research, Acton, MA
- Michael J. Zinda, AstraZeneca R&D Boston, Waltham, MA
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 3: Optimizing Drug Discovery: Insights on an Important Process
Chairperson: Michael J. Luzzio, Novartis Institutes for BioMedical Research, Cambridge, MA
- John Flygare, Genentech, Inc., South San Francisco, CA
- Robert L. Hoffman, Pfizer Global Research & Development, San Diego, CA
- Michael J. Luzzio
- Joseph P. Lyssikatos, Genentech, Inc., South San Francisco, CA
- Michael Shultz, Novartis, Cambridge, MA
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Chemical Development: Translating a Potent Agent into a Registered Product
Chairperson: Stephen A. Munk, Ash Stevens, Inc., Detroit, MI
- David Mitchell, Eli Lilly and Company, Indianapolis, IN
- Stephen A. Munk
- Sanjeev Redkar, Astex Pharmaceutical Inc., Dublin, CA
- Gita Shankar, SRI International, Menlo Park, CA
The Genetic Basis of Cancer Susceptibility: Molecular Testing to Clinical Surveillance
Chairperson: David Malkin, University of Toronto Hospital for Sick Children, Toronto, ON, Canada
- David Malkin
- Yael P. Mosse, Children's Hospital of Philadelphia, Philadelphia, PA
- Joshua D. Schiffman, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
- Rosanna Weksberg, University of Toronto Hospital for Sick Children, Toronto, ON, Canada
The Hypoxic Tumor Microenvironment as a Target for Cancer Therapy
Chairperson: Giovanni Melillo, Bristol-Myers Squibb Co., Princeton, NJ
- Juri G. Gelovani, The University of Texas MD Anderson Cancer Center, Houston, TX
- Adrian L. Harris, University of Oxford, Oxford, United Kingdom
- Giovanni Melillo
- William Robert Wilson, University of Auckland Cancer Society Research Center, Auckland, New Zealand
Interrupting the PI3K-AKT-mTOR Pathway in Cancer Therapy
Chairperson: Steven Grant, VCU Massey Cancer Center, Richmond, VA
- Phillip A. Dennis, National Cancer Institute, Bethesda, MD
- Jeffrey A. Engelman, Massachusetts General Hospital, Boston, MA
- Leonidas C. Platanias, Northwestern University Lurie Comprehensive Cancer Center, Chicago, IL
- David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY
Introduction to Interpretation of Clinical Trial Results: A Primer for Basic Scientists
Co-Chairpersons: Philippe L. Bedard, University of Toronto University Health Network, Toronto, ON, Canada; and Lee M. Ellis. The University of Texas MD Anderson Cancer Center, Houston, TX
- Philippe L. Bedard
- Lee M. Ellis
- Mark J. Ratain, University of Chicago, Chicago, IL
- Ian F. Tannock, University of Toronto University Health Network, Toronto, ON, Canada
- Emile E. E. Voest, University Medical Center Utrecht, Utrecht, The Netherlands
Melanoma: Moving Beyond BRAF
Chairperson: Michael A. Davies, The University of Texas MD Anderson Cancer Center, Houston, TX
- Boris C. Bastian, UCSF Cardiovascular Research Institute, San Francisco, CA
- Michael A. Davies
- Keiran S.M. Smalley, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
- Scott Woodman, The University of Texas MD Anderson Cancer Center, Houston, TX
Molecular and Systems Pathology in Human Cancer: From Translational Research to Clinical Practice
Chairperson: Carlos Cordon-Cardo, Columbia University, New York, NY
- Julide Tok Celebi, Columbia University, New York, NY
- Carlos Cordon-Cardo
- Janina A. Longtine, Brigham and Women's Hospital, Boston, MA
- Ila Singh, Mount Sinai Medical Center, New York, NY
Molecular Mechanisms of Mature B-Cell Neoplasia
Chairperson: P. Lief Bergsagel, Mayo Clinic Arizona, Scottsdale, AZ
- P. Lief Bergsagel
- Riccardo Dalla-Favera, Columbia University Irving Comprehensive Cancer Center, New York, NY
- Randy D. Gascoyne, BC Cancer Agency, Vancouver, BC, Canada
- Sami N. Malek, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Myelodysplastic Syndromes: New Pathways and Treatment
Chairperson: Olivier Bernard, Institut Gustave-Roussy, Villejuif, France
- Michaela Fontenay, Université Paris Descartes, Paris, France
- Timothy Graubert, Washington University School of Medicine, St. Louis, MO
- Seishi Ogawa, University of Tokyo, Bunkyo-Ku, Japan
- David P. Steensma, Dana-Farber Cancer Institute, Boston, MA
Myeloid Cells and Immune Reprogramming in Solid Tumors: New Targets for Therapy
Chairperson: Lisa M. Coussens, Knight Cancer Institute, Oregon Health and Science University, Portland, OR
- Michele De Palma, The Swiss Institute for Experimental Cancer Research, Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland
- Luisa Iruela-Arispe, University of California, Los Angeles, CA
- Anna Karolina Palucka, Baylor Institute for Immunology Research, Dallas, TX
- Mikael J. Pittet, Massachusetts General Hospital, Boston, MA
Nonapoptotic Cell Death Mechanisms: Autophagy, Necroptosis, and Beyond
Chairperson: Guido Kroemer, INSERM U848, Institut Gustave-Roussy, Villejuif, France
- Erik H. Baehrecke, University of Massachusetts Medical School, Worcester, MA
- Simone Fulda, J.W. Goethe University of Frankfurt, Frankfurt, Germany
- Guido Kroemer
- Seamus J. Martin, Trinity College Dublin, Dublin, Ireland
Novel Targets in Hematologic Malignancies
Chairperson: Elizabeth A. Eklund, Northwestern University, Chicago, IL
- Hetty E. Carraway, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
- Martin Carroll, University of Pennsylvania, Philadelphia, PA
- Elizabeth A. Eklund
- Jolanta Grembecka, University of Michigan, Ann Arbor, MI
Nuclear Receptors as Therapeutic Targets in Cancer
Chairperson: Donald P. McDonnell, Duke University Medical Center, Durham, NC
- Orla M. Conneely, Baylor College of Medicine, Houston, TX
- Vincent Giguère, McGill University Goodman Cancer Center, Montreal, QC, Canada
- Carol Lange, University of Minnesota Masonic Cancer Center, Minneapolis, MN
- John D. Minna, The University of Texas Southwestern Medical Center, Dallas, TX
Nutritionally Based Cancer Risk Reductive Interventions
Chairperson: Dean E. Brenner, University of Michigan Medical Center, Ann Arbor, MI
- Dean E. Brenner
- Stephen D. Hursting, University of Texas at Austin, Austin, TX
- Madhuri Kakarala, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
- William P. Steward, University of Leicester, Leicester, United Kingdom
Prostate Cancer Mouse Models
Chairperson: Michael M. Shen, Columbia University, New York, NY
- Brett S. Carver, Memorial Sloan-Kettering Cancer Center, New York, NY
- Eva Corey, University of Washington, Seattle, WA
- Simon W. Hayward, Vanderbilt University Medical Center, Nashville, TN
- Michael M. Shen
The Role of Infectious Agents in Cancer
Chairperson: Larry Corey, Fred Hutchinson Cancer Research Center, Seattle, WA
- Corey Casper, Fred Hutchinson Cancer Research Center, Seattle, WA
- Stephen J. Polyak, University of Washington, Seattle, WA
- Timothy R. Rebbeck, University of Pennsylvania School of Medicine, Philadelphia, PA
- Sankar Swaminathan, University of Utah School of Medicine, Salt Lake City, UT
Targeting the Epigenome to Treat Cancer
Chairperson: Ricky W. Johnstone, Peter MacCallum Cancer Center, Melbourne, Australia
- Robert A. Copeland, EpiZyme, Inc., Cambridge, MA
- Mark A. Dawson, Cambridge Institute for Medical Research, Cambridge, United Kingdom
- Ricky W. Johnstone
- Johannes Zuber, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Targeting the p53 Tumor Suppressor Pathway in Cancer Therapy
Chairperson: James J. Manfredi, Mt. Sinai School of Medicine, New York, NY
- David P. Lane, A*STAR, Singapore
- James J. Manfredi
- Jennifer A. Pietenpol, Vanderbilt-Ingram Cancer Center, Nashville, TN
- Lyubomir T. Vassilev, Hoffmann-La Roche, Inc., Nutley, NJ
Tumor Immunology for the Non-Immunologist
Chairperson: Hyam I. Levitsky, Hoffman-La Roche, Inc., Nutley, NJ
- Wolf Hervé Fridman, Unité INSERM, Paris, France
- Hyam I. Levitsky
- Michel Sadelain, Memorial Sloan-Kettering Cancer Center, New York, NY
- Eduardo M. Sotomayor, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Understanding Cancer Metabolism Pathways
Chairperson: Navdeep S. Chandel, Northwestern University, Chicago, IL
- Ralph J. DeBerardinis, UT Southwestern Medical Center, Dallas, TX
- Georgia Hatzivassiliou, Genentech, Inc., South San Francisco, CA
- Nissim Hay, University of Illinois at Chicago, Chicago, IL
- Matthew G. Vander Heiden, MIT Koch Institute for Integrated Cancer Research, Cambridge, MA
|